Stock Market Reviews

Read and share opinions on NGNE (Neurogene Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Neurogene: Q3 Earnings Snapshot
  Nov 13, 2025
• Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
  Nov 13, 2025
• Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
  Nov 12, 2025
• Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
  Nov 6, 2025
• Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  Nov 5, 2025
• Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
  Oct 9, 2025
• Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
  Oct 8, 2025
• Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Oct 3, 2025
• Neurogene: Q2 Earnings Snapshot
  Aug 11, 2025
• Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
  Aug 11, 2025
• Bullish Neurogene Insiders Loaded Up On US$1.46m Of Stock
  Jul 30, 2025
• Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
  Jun 30, 2025
• Craig-Hallum bullish on Neurogene, initiates with a Buy
  Jun 18, 2025
• Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV
  May 16, 2025
• Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
  May 9, 2025
• Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
  Apr 28, 2025
• Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome
  Apr 2, 2025